ClinicalTrials.gg
CompletedNCT00112918Updated Aug 27, 2013Results posted

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

A Phase 3 interventional study of Bevacizumab and Capecitabine in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-27.

Primary conditionColonic NeoplasmsRegistry: Colorectal NeoplasmsReclassifiedWhy we changed it
Registry
Colorectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colonic Neoplasms
Why
  1. The study's title name Colonic Neoplasms, a narrower term within Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,451
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies testing bevacizumab in Colonic Neoplasms — 5 open to participants now, 7 under way, 1 of them phase 3. Bevacizumab · Colonic Neoplasms.

Enrollment
Largest of 68
3,451 · median 49
Started
2004
with 3 others
Phase 3
11 of 71
none open now
Registered
12th of 71
by date

Among the 71 studies testing bevacizumab in Colonic Neoplasms, this one has the largest enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2004, is one of 11 in phase 3, and was the 12th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

5 of the 71 studies testing bevacizumab in Colonic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing bevacizumab in Colonic Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab (Bv) may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer in adjuvant setting.

PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens with or without bevacizumab to compare how well they work in treating patients who have undergone surgery for high risk stage II or stage III colon cancer.

Read the detailed description

This was an open-label Phase III, multicenter, multinational, randomized, 3-arm study designed to evaluate the efficacy and safety of bevacizumab in combination with either intermittent fluorouracil/leucovorin with oxaliplatin (FOLFOX4) or capecitabine plus oxaliplatin (XELOX) versus FOLFOX4 regimen alone, as adjuvant chemotherapy in colon carcinoma.

The treatment phase consisted of two parts of 24 weeks for a total of 48 weeks. The first part (weeks 1 to 24) consisted of treatment with either FOLFOX4, FOLFOX4 in combination with bevacizumab, or XELOX in combination with bevacizumab. The second part (weeks 25 to 48) consisted of single-agent bevacizumab for patients randomized to either bevacizumab-containing arm, but was only an observation period for patients assigned to the FOLFOX4-alone arm.

Patients were to be followed for recurrence/new occurrence of colorectal cancer and survival. Patients who experienced a confirmed recurrence, occurrence of a new colorectal cancer during therapy, or experienced unacceptable toxicity were to be taken off study treatment but remain in study follow-up. Patients that came off therapy due to a confirmed recurrence/appearance of new colorectal cancer, were to be followed for survival until the end of the study follow-up period. The primary analysis was performed 36 months after the last patient has been randomized. After the primary analysis, patients continue to be followed for survival for at least a further 2 years ie, until all patients have been followed-up for at least 5 years following randomization.

03

Conditions studied

  • Colorectal Cancer

Browse trials for

Keywords

  • stage II colon cancer
  • stage III colon cancer
04

In context

Colonic Neoplasms Reclassified

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

This study's enrollment of 3,451 is above the median of 75 across 1,710 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Colonic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written obtained prior to any study specific screening procedures.
  2. Patient willing and able to comply with the protocol.
  3. Age ≥ 18 years-of-age.
  4. confirmed colon carcinoma, American Joint Cancer Committee/Union Internationale Contre le Cancer (AJCC/UICC) Stage II or Stage III defined as a tumor location ≥ 15 cm from the anal verge by endoscopy or above the peritoneal reflection at surgery. The patient was not to be a candidate for (neo) radiotherapy. Note: Stage II patients were to be considered as high-risk patients fulfilling one of the following criteria:

    • T4 tumours,
    • Patients presenting with bowel obstruction or perforation,
    • Histological signs of vascular invasion (i.e. blood and lymphatic vessels) or perineural invasion,
    • Patients aged less than 50 years,
    • Patients with sub-optimal surgery (less than 12 nodes analyzed).
  5. Curative surgery not less than 4 and not more than 8 weeks prior to randomization.
  6. (ECOG) performance status 0 or 1.
  7. of ≥ 5 years.

Exclusion criteria

Exclusion Criteria

  1. Macroscopic or microscopic evidence of remaining tumour. Patients should never have had any evidence of disease (including presence of tumour cells in the ascites). The isolated finding of cytokeratin positive cells in bone marrow is not considered evidence of metastatic disease for purposes of this study.
  2. Carcinoembryonic antigen > 1.5 x (ULN) after surgery (during screening period).
  3. For patients with colostomy, unwilling to delay revision until at least 28 days after treatment completion.
  4. Major surgical procedure, open , or significant traumatic injury within 28 days prior to study treatment start, not fully healed wounds, or anticipation of the need for major surgical procedure during the course of the study. Any central venous access device (CVAD) for chemotherapy administration must be inserted at least 2 days prior to treatment start.
  5. Previous anti-angiogenic treatment for any ; cytotoxic chemotherapy, radiotherapy or immunotherapy for colon cancer.
  6. Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
  7. Females with a positive or no pregnancy test (within 7 days before treatment start) unless can be otherwise excluded ( i.e. amenorrheic for at least 2 years, hysterectomy or oophorectomy).
  8. Lactating women.
  9. Fertile women (\< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of .
  10. History or evidence upon physical examination of central nervous disease (CNS) disease (eg, primary brain tumour, seizure not controlled with standard medical therapy, any ).
  11. History of psychiatric disability judged by the investigator to be , precluding or interfering with compliance for oral drug intake.
  12. Clinically significant (ie, active) cardiovascular disease. This includes, but is not limited to, the following examples: cerebrovascular accidents (≤ 6 months prior to randomization), myocardial infarction (≤ 1 year prior to randomization), uncontrolled hypertension (>150/100 mmHg) while receiving chronic medication, unstable angina, (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, clinically significant (ECG) findings (e.g. ≥ 440 msecs [male] 460 msecs [female] or ≥ 2º atrioventricular block, etc.).

    Patients who suffer from serious cardiac arrhythmia requiring medication can enter the study only if they are considered to be in a stable condition regarding both the arrhythmia and their medication. Patients with pacemakers are allowed to enter the study only if they are considered as being in a stable condition. In case of doubt, the investigator should obtain a consultation with a local cardiologist.

  13. Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication.
  14. Interstitial pneumonia or extensive symptomatic fibrosis of the lungs.
  15. Known peripheral neuropathy ≥ (CTCAE) version 3.0 Grade 1. Absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible.
  16. Organ allografts requiring therapy.
  17. Serious, non-healing wound, ulcer, or bone fracture.
  18. Evidence of bleeding diathesis or coagulopathy.
  19. Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes.
  20. Chronic, daily treatment with high-dose aspirin (> 325 mg/day) or clopidogrel (> 75 mg/day).
  21. Chronic treatment with (dose of ≥ 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids).
  22. Serious intercurrent infections (uncontrolled or requiring treatment).
  23. Known dihydropyrimidine dehydrogenase deficiency.
  24. Current or recent (within the 28 days prior to randomization) treatment with another drug or participation in another investigational study.
  25. Patients with known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanized antibodies or to any of bevacizumab formulation, platinum compounds or to any other components of the study drugs.
  26. History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications.
  27. Presence of proteinuria at baseline as defined by:

    • Patients with > 1 g of protein/24 hour by a 24-hour urine collection.
  28. Any laboratory values at baseline are as follows:

Haematology:

  • (ANC) \< 1.5 x 109/L
  • count \< 100 x 10\^9/L
  • \< 9 g/dL (may be transfused to maintain or exceed this level)
  • (INR) > 1.5
  • Activated partial prothrombin time (APTT) ≥ 1.5 x ULN

Biochemistry:

  • Total > 1.5 x ULN
  • (ASAT), alanine aminotransferase (ALAT) > 2.5 x ULN
  • Alkaline phosphatase (ALP) > 2.5 x ULN
  • Serum creatinine > 1.5 x ULN or ≤ 50 mL/min (e.g. Cockcroft-Gault formula).
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,451 participants (actual)

Study arms

  • Active comparator
    FOLFOX4

    Weeks 1-24: Oxaliplatin was administered as an 85 mg/m\^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\^2 bolus injection, and then as a 600 mg/m\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\^2 (alone), followed by 5-FU 400 mg/m\^2 bolus injection, and 5-FU 600 mg/m\^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks). Weeks 25-48: Observation only.

    Drug: 5-Fluorouracil (5-FU) · Drug: Leucovorin calcium · Drug: Oxaliplatin

  • Experimental
    FOLFOX4 + Bv

    Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m\^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\^2 bolus injection, and then as a 600 mg/m\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\^2 (alone), followed by 5-FU 400 mg/m\^2 bolus injection, and 5-FU 600 mg/m\^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks). Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).

    Biological: Bevacizumab · Drug: 5-Fluorouracil (5-FU) · Drug: Leucovorin calcium · Drug: Oxaliplatin

  • Experimental
    XELOX+Bv

    Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m\^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m\^2 twice daily (equivalent to a total daily dose of 2000 mg/m\^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks). Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).

    Biological: Bevacizumab · Drug: Capecitabine · Drug: Oxaliplatin

Interventions

  • BiologicalBevacizumab

    Administered as an intravenous infusion over 30 - 90 minutes.

  • Film-coated tablets

    Also known as: Xeloda®

  • Administered as either a bolus injection or continuous intravenous infusion over 22 hours.

  • Administered as a 200 mg/m\^2 infusion over 2 hours.

  • Administered as an intravenous infusion over 2 hours.

07

What researchers measure

Primary outcomes

  1. Disease-free Survival in Stage III Cancer Patients - Time to Event

    Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1.

    Time frame: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).

  2. Disease-free Survival in Stage III Cancer Patients - Number of Events

    A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer.

    Time frame: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).

Secondary outcomes

  1. Overall Survival in Stage III Cancer Patients - Time to Event

    Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive.

    Time frame: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).

  2. Overall Survival in Stage III Cancer Patients - Number of Events

    An overall survival event was death due to any cause.

    Time frame: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).

  3. Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis

    Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive.

    Time frame: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).

  4. Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis

    An overall survival event was death due to any cause.

    Time frame: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).

08

Results

Posted Sep 6, 2012

Participant flow

Participant flow — Overall Study
MilestoneFOLFOX4FOLFOX4 + BvXELOX+Bv
Started115111551145
Received treatment112611451135
Stage iii disease population955960952
Completed854810846
Not completed297345299

Outcome measures

PrimaryDisease-free Survival in Stage III Cancer Patients - Time to Event

Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1.

Time frame:
From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
Reported as:
Median · months
Disease-free Survival in Stage III Cancer Patients - Time to Event
monthsFOLFOX4FOLFOX4 + BvXELOX+Bv
Disease-free Survival in Stage III Cancer Patients - Time to EventNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • FOLFOX4 vs FOLFOX4 + Bv vs XELOX+Bv · Closed test procedure · p = 0.2024
SecondaryOverall Survival in Stage III Cancer Patients - Time to Event

Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive.

Time frame:
From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
Reported as:
Median · months
Overall Survival in Stage III Cancer Patients - Time to Event
monthsFOLFOX4FOLFOX4 + BvXELOX+Bv
Overall Survival in Stage III Cancer Patients - Time to EventNA (NA to NA)NA (NA to NA)NA (NA to NA)
PrimaryDisease-free Survival in Stage III Cancer Patients - Number of Events

A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer.

Time frame:
From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
Reported as:
Number · participants
Disease-free Survival in Stage III Cancer Patients - Number of Events
participantsFOLFOX4FOLFOX4 + BvXELOX+Bv
Patients with a DFS event237280253
Recurrence219253223
New Occurrence386
Death172125
Patients without events718680699
SecondaryOverall Survival in Stage III Cancer Patients - Number of Events

An overall survival event was death due to any cause.

Time frame:
From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
Reported as:
Number · participants
Overall Survival in Stage III Cancer Patients - Number of Events
participantsFOLFOX4FOLFOX4 + BvXELOX+Bv
Patients with events115151145
Patients without events840809807
SecondaryOverall Survival in Stage III Cancer Patients - Time to Event: Final Analysis

Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive.

Time frame:
From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
Reported as:
Median · months
Overall Survival in Stage III Cancer Patients - Time to Event: Final Analysis
monthsFOLFOX4FOLFOX4 + BvXELOX+Bv
Overall Survival in Stage III Cancer Patients - Time to Event: Final AnalysisNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival in Stage III Cancer Patients - Number of Events: Final Analysis

An overall survival event was death due to any cause.

Time frame:
From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
Reported as:
Number · participants
Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis
participantsFOLFOX4FOLFOX4 + BvXELOX+Bv
Patients with events161202182
Patients without events794758770

Adverse events

Collected over All adverse events occurring between the date of first drug intake and 28 days after last drug intake, regardless of which treatment group the patient was randomized to.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FOLFOX4—226/1,126 (20.1%)1,112/1,126 (98.8%)
FOLFOX4 + Bv—297/1,145 (25.9%)1,127/1,145 (98.4%)
XELOX+Bv—284/1,135 (25%)1,117/1,135 (98.4%)
Most frequent serious events
Showing 10 of 329
Most frequent serious events
EventFOLFOX4FOLFOX4 + BvXELOX+Bv
DiarrhoeaGastrointestinal disorders28/112628/114562/1135
PyrexiaGeneral disorders20/112610/114516/1135
NeutropeniaBlood and lymphatic system disorders18/112618/11450/1135
Abdominal painGastrointestinal disorders11/112614/114518/1135
DehydrationMetabolism and nutrition disorders7/112610/114517/1135
VomitingGastrointestinal disorders7/112611/114516/1135
Deep vein thrombosisVascular disorders9/112616/114512/1135
Pulmonary embolismRespiratory, thoracic and mediastinal disorders11/112615/114510/1135
Febrile neutropeniaBlood and lymphatic system disorders14/11269/11452/1135
HypertensionVascular disorders1/11262/114513/1135
Most frequent other events
Showing 10 of 55
Most frequent other events
EventFOLFOX4FOLFOX4 + BvXELOX+Bv
NauseaGastrointestinal disorders725/1126761/1145720/1135
DiarrhoeaGastrointestinal disorders620/1126699/1145699/1135
NeutropeniaBlood and lymphatic system disorders660/1126567/1145273/1135
HypertensionVascular disorders196/1126472/1145468/1135
VomitingGastrointestinal disorders385/1126394/1145460/1135
Peripheral sensory neuropathyNervous system disorders430/1126430/1145436/1135
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders98/1126119/1145435/1135
FatigueGeneral disorders404/1126425/1145355/1135
EpistaxisRespiratory, thoracic and mediastinal disorders228/1126424/1145216/1135
StomatitisGastrointestinal disorders310/1126360/1145246/1135

Baseline characteristics

Baseline Measures are based on the Intent-to-Treat - Stage III Disease Patient Population.

Age, Customized
Age, Customized(participants)FOLFOX4FOLFOX4 + BvXELOX+BvTotal
<40777468219
40-656036255881816
>=65275261296832
Sex: Female, Male
Sex: Female, Male(Participants)FOLFOX4FOLFOX4 + BvXELOX+BvTotal
Female4254734321330
Male5304875201537
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FOLFOX4FOLFOX4 + BvXELOX+BvTotal
American Indian or Alaska Native1102
Asian139115123377
Black or African American6131433
White7918137952399
Other18182056
09

Study locations

1 site
  • Jonsson Comprehensive Cancer Center at UCLA
    Los Angeles, California 90095-1781, United States
10

References and documents

Publications

  • Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, Andre T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023 Feb 1;41(4):803-815. doi: 10.1200/JCO.21.02726. Epub 2022 Oct 28. PubMed 36306483 ↗
  • Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, Andre T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2021 Feb 20;39(6):642-651. doi: 10.1200/JCO.20.01600. Epub 2020 Dec 23. PubMed 33356421 ↗
  • Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, Andre T, de Gramont A. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. JAMA Netw Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. Erratum In: JAMA Netw Open. 2021 Feb 1;4(2):e210700. doi: 10.1001/jamanetworkopen.2021.0700. PubMed 33074326 ↗
  • Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020 Apr;31(4):480-486. doi: 10.1016/j.annonc.2019.12.007. Epub 2020 Jan 16. PubMed 32085892 ↗
  • Andre T, Vernerey D, Im SA, Bodoky G, Buzzoni R, Reingold S, Rivera F, McKendrick J, Scheithauer W, Ravit G, Fountzilas G, Yong WP, Isaacs R, Osterlund P, Liang JT, Creemers GJ, Rakez M, Van Cutsem E, Cunningham D, Tabernero J, de Gramont A. Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. Ann Oncol. 2020 Feb;31(2):246-256. doi: 10.1016/j.annonc.2019.12.006. Epub 2019 Dec 18. PubMed 31959341 ↗
  • Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208. PubMed 31268130 ↗
  • de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, Andre T, Hoff PM. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16. PubMed 23168362 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jun 2010 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2005
First posted
Jun 3, 2005
Start
Dec 2004
Primary completionActual
Jun 2010
CompletionActual
Jun 2012
Results first posted
Sep 6, 2012
Last update
Aug 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00112918
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 3, 2005
Start date
Dec 2004
Primary completion
Jun 2010
Completion
Jun 2012
Results posted
Sep 6, 2012
Last update
Aug 27, 2013

Study contacts

Joel Randolph Hecht, MD
principal investigator · Jonsson Comprehensive Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Capecitabine

Start the discussion